期刊
INTERNATIONAL JOURNAL OF STROKE
卷 18, 期 4, 页码 383-391出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/17474930221150349
关键词
Antiphospholipid syndrome; antiphospholipid antibodies; ischemic stroke; cerebrovascular disorders; cognitive impairment; antithrombotic
Antiphospholipid syndrome (APS) is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA). It has a wide spectrum of cerebrovascular lesions, including white matter hyperintensities, cortical atrophy, and infarcts, with clinically important neurocognitive sequalae. The diagnosis and management of APS-associated AIS/TIA require expert evaluation, and there are uncertainties regarding optimal antithrombotic therapy for secondary prevention.
Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider spectrum of APS-associated cerebrovascular lesions, including white matter hyperintensities, cortical atrophy, and infarcts, which may have clinically important neurocognitive sequalae. Diagnosis of APS-associated AIS/TIA requires expert review of clinical and laboratory information. Management poses challenges, given the potential for substantial morbidity and recurrent thrombosis, additional risk conferred by conventional cardiovascular risk factors, and limited evidence base regarding optimal antithrombotic therapy for secondary prevention. In this review, we summarize key features of APS-associated cerebrovascular disorders, with focus on clinical and laboratory aspects of diagnostic evaluation. The current status of prognostic markers is considered. We review the evidence base for antithrombotic treatment in APS-associated stroke and discuss uncertainties, including the optimal intensity of anticoagulation and efficacy of direct oral anticoagulants. Clinical practice recommendations are provided, covering antithrombotic treatment, supportive management, and options for anticoagulant-refractory cases, and we highlight the benefits of adopting a considered, multidisciplinary team approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据